Cantitate/Preț
Produs

HMG-CoA Reductase Inhibitors: Milestones in Drug Therapy

Editat de Gerd Schmitz, Michael Torzewski
en Limba Engleză Paperback – 30 oct 2012
HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume...
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 70858 lei  6-8 săpt.
  Birkhäuser Basel – 30 oct 2012 70858 lei  6-8 săpt.
Hardback (1) 128315 lei  6-8 săpt.
  Birkhäuser Basel – 23 oct 2002 128315 lei  6-8 săpt.

Din seria Milestones in Drug Therapy

Preț: 70858 lei

Preț vechi: 74588 lei
-5% Nou

Puncte Express: 1063

Preț estimativ în valută:
13560 14139$ 11270£

Carte tipărită la comandă

Livrare economică 21 martie-04 aprilie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783034894517
ISBN-10: 3034894511
Pagini: 164
Ilustrații: X, 151 p.
Dimensiuni: 155 x 235 x 9 mm
Greutate: 0.24 kg
Ediția:Softcover reprint of the original 1st ed. 2002
Editura: Birkhäuser Basel
Colecția Birkhäuser
Seria Milestones in Drug Therapy

Locul publicării:Basel, Switzerland

Public țintă

Research

Cuprins

History and development of HMG-CoA reductase inhibitors.- Structure and mechanisms of action of HMG-CoA reductase inhibitors.- Sterol-regulatory element binding proteins (SREBPs): gene-regulatory target of statin action.- Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets).- Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall.- Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia).- Clinical experience: studies with HMG-CoA reductase inhibitors.- Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease.

Caracteristici

Includes supplementary material: sn.pub/extras